Ferritin, zinc, magnesium: the biological terrain of ADHD

The standard psychiatric scope covers behavioural diagnosis and treatment prescription. It does not include routine testing of the biological cofactors of dopamine. This is not an oversight, it is a care organisation: the psychiatrist does not practise functional medicine.

The practical consequence is that an adult with ADHD can be correctly diagnosed, correctly treated, and remain a sub-responder because ferritin at 25 ng/mL is throttling tyrosine hydroxylase" data-lang="en">tyrosine hydroxylase, or because crashed magnesium is sustaining rebound insomnia. This is precisely the angle a naturopathic or functional-medicine accompaniment covers, alongside, never instead of, psychiatric care.

tyrosine hydroxylase" data-lang="en">Tyrosine hydroxylase, the rate-limiting enzyme of dopamine synthesis, uses iron as a cofactor. Low ferritin reduces its activity, independently of whether overt anaemia is present or not. Adult clinical literature points to a functional threshold around 50 to 80 ng/mL, well above the classical hospital threshold of 15 ng/mL.

The clinical impact is documented: low ferritin attenuates the response to methylphenidate and amplifies some side effects (paradoxical fatigue, dry mouth, sensitivity to mood swings). Correcting it upstream, with a well-tolerated form (iron bisglycinate or heme iron) and biological follow-up, is one of the high-impact, low-cost levers of an ADHD work-up.

Zinc participates in the regulation of the DAT transporter and the stability of dopaminergic receptors. Serum zinc poorly reflects real status, as it is rapidly buffered. Erythrocyte zinc gives a more stable measure of tissue status and better guides supplementation.

Blind supplementation is to be avoided: chronically excessive zinc blocks copper absorption and destabilises antioxidant status. The rule: test, then correct over a few months with follow-up, and stop once the target is reached.

Magnesium is involved in over 300 enzymatic reactions, several linked to the regulation of the sympathetic axis and sleep. Serum is uninformative (tight homeostasis), the erythrocyte form better reflects cellular availability.

The galenic form is decisive: bisglycinate (or glycinate) crosses the blood-brain barrier and clinically supports sleep onset and rebound anxiety, unlike oxide or carbonate, which are poorly bioavailable. Citrate is useful for digestive regulation but less so for the brain. This is a distinction that concretely changes the clinical experience.

Vitamin D modulates dopaminergic receptor expression (notably DRD2) and participates in immune and inflammatory regulation. Deficit (25(OH)D below 30 ng/mL) is massively prevalent in France, including in young adults in temperate zones, and is associated in several studies with greater ADHD symptom severity.

Targeting 25(OH)D between 40 and 60 ng/mL is a conservative, sustainable recommendation. Supplementation is titrated to the initial deficit, with a 3-month follow-up.

B vitamins sit at the heart of catecholamine synthesis and methylation. B6 (P5P) is a cofactor for the decarboxylation of L-DOPA into dopamine. B12 and erythrocyte folate support the methylation pathway, on which the inactivation of catecholamines by COMT and the synthesis of SAMe depend.

Homocysteine above 10 µmol/L is an indirect marker of suboptimal methylation and points toward targeted support. In carriers of an MTHFR C677T polymorphism, using methylfolate rather than synthetic folic acid can be relevant, but must be individualised: excess methyl donors can amplify anxiety and irritability in some profiles.

The erythrocyte omega-3 index" data-lang="en">omega-3 index measures the percentage of EPA and DHA in red blood cell membranes. It reflects real membrane incorporation over several months, unlike plasma testing, which is sensitive to the last meal.

Target: above 8%. Many French adults sit between 3 and 5%. Effective supplementation goes through a re-esterified triglyceride (rTG) form, with dosing adapted to the gap between measured index and target. It is a valuable marker to objectify adherence and adjust without guesswork.

Three mushrooms come up in the literature relevant to adult ADHD terrain:

• Hericium erinaceus (lion's mane): solid preclinical data on NGF and BDNF induction, and first 2024-2025 human studies on cognition and mood. Effects observed over 8 to 16 weeks.
• Ganoderma lucidum (Reishi): documented action on neuroinflammation, the HPA axis, sleep. Relevant in anxious comorbidity.
• Cordyceps: support for cognitive hypo-arousal profiles (fatigue, brain fog), via mitochondrial function.

Direct clinical evidence in ADHD remains limited: these molecules are used as terrain support, not as treatment, and always with verified raw-material quality.

There is no universal ADHD protocol. The same symptom (insomnia, irritability, end-of-day fatigue) can stem from very different biological mechanisms from one person to another. Blind supplementation, based on an article or a generic recommendation, exposes the person to real counterproductive effects.

Individualised accompaniment means testing first, correcting next with adapted galenic forms, and reassessing after 8 to 16 weeks. It is slower than random supplementation, and infinitely more cost-effective.